



FOR IMMEDIATE RELEASE

**Merrimack Pharmaceuticals to Present at
CIBC Biotechnology and Specialty Pharmaceuticals Conference**

CAMBRIDGE, Mass., March 26, 2007 – Merrimack Pharmaceuticals today announced that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York. Bob Mulroy, President and Chief Executive Officer will provide a company overview at 3:40pm EDT, Wednesday, April 11, 2007 at the Millennium Broadway Hotel in New York City.

About Merrimack

Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis, psoriasis or with autoimmune uveitis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is a privately held company based in Cambridge, Massachusetts. For additional information, please visit <http://www.merrimackpharma.com>.

Contact:

Kathleen Petrozzelli, Manager, Corporate Communications, 617-441-1043